

PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Vesicular Monoamine Transporter Type 2 Inhibitors Preferred Specialty Management Policy

- Xenazine® (tetrabenazine tablets – Lundbeck, generic)

REVIEW DATE: 04/10/2024

OVERVIEW

Tetrabenazine, a reversible vesicular monoamine transporter type 2 (VMAT2) inhibitor, is indicated for the treatment of **chorea associated with Huntington’s disease**.¹

Clinical Efficacy

There are several published studies which have assessed the efficacy and safety of tetrabenazine for the treatment of other hyperkinetic movement disorders (e.g., tics in Tourette syndrome and tardive dyskinesia).²

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of the Preferred Product. For all medications (Preferred and Non-Preferred), the patient is required to meet the standard *Vesicular Monoamine Transporter Type 2 Inhibitors Prior Authorization Policy* criteria. The program also directs the patient to try the Preferred Product (generic tetrabenazine tablets). Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). If the patient meets the standard *Prior Authorization Policy* criteria but has not tried a Preferred Product, approval for a Preferred Product will be authorized. All approvals are provided for 1 year.

Documentation: Documentation is required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, prescription receipts, and/or other information.

Automation: None

Preferred Product: Generic tetrabenazine tablets
Non-Preferred Product: Xenazine

RECOMMENDED EXCEPTION CRITERIA

REFERENCES

1. Xenazine® tablets [prescribing information]. Deerfield, IL: Lundbeck; November 2019.
2. Merative Micromedex®. Merative US. Available at: www.micromedexsolutions.com. Accessed on April 3, 2024. Search terms: tetrabenazine.